Concepedia

Steady-state Bioavailability

Steady-State Bioavailability is a pharmacokinetic metric that quantifies the extent of active drug availability at the systemic circulation following repeated dosing regimens once equilibrium between drug administration and elimination has been achieved, differing from absolute bioavailability by reflecting bioavailability under conditions of constant, prolonged exposure rather than a single dose.

27

Publications

800

Citations

120

Authors

46

Institutions

Publications per year

2017–2026

1

Parents

Publications

27

Direct measurement of propranolol bioavailability during accumulation to steady‐state.

AJ Wood, K. Carr, R. E. Vestal et al. · British Journal of Clinical Pharmacology · 1978 · 125 citations · Full text

, , +17

Determination of bioavailability of diazepam in various formulations from steady state plasma concentration data

Anita Berlin, Bo Siwers, Stig Agurell et al. · Clinical Pharmacology & Therapeutics · 1972 · 99 citations

, , +17

Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study

Elliot Offman, Ted Marenco, Sandy Ferber et al. · Vascular Health and Risk Management · 2013 · 91 citations · Full text

, , +14

Steady-state bioavailability of controlled-release oxycodone in normal subjects

Robert F. Reder · Clinical Therapeutics · 1996 · 53 citations

, , +15

The comparative steady-state bioavailability of the active ingredients of madecassol

W. R. Rush, G. R. Murray, D. J. M. Graham · European Journal of Drug Metabolism and Pharmacokinetics · 1993 · 44 citations

, , +11

1–5 of 27

Authors

120

  1. RG
    Richard Gural

    Bloomfield College, United States

    2 publications · 33 citations

    2

    h-index

  2. CP
    Christopher P. Brezovic

    Procter & Gamble (United States), United States

    2 publications · 29 citations

    2

    h-index

  3. AB
    Akshay Buch

    Procter & Gamble (United States), United States

    2 publications · 29 citations

    2

    h-index

  4. LZ
    Larry Z. Shen

    Amplyx Pharmaceuticals (United States), United States

    2 publications · 29 citations

    2

    h-index

  5. CB
    Carol Bixler

    Procter & Gamble (United States), United States

    2 publications · 29 citations

    2

    h-index

1–5 of 120

Institutions

46

  1. Procter & Gamble (United States)

    Cincinnati, United States

    2 h-index

    8 publications

    107 citations

  2. Janssen (Belgium)

    Beerse, Belgium

    2 h-index

    10 publications

    190 citations

  3. Purdue Pharma (United States)

    Stamford, United States

    1 h-index

    1 publications

    53 citations

  4. Hassman Research Institute

    Berlin, United States

    1 h-index

    1 publications

    17 citations

  5. University of Hertfordshire

    Hatfield, United Kingdom

    1 h-index

    3 publications

    33 citations

  6. Center for Biologics Evaluation and Research

    Silver Spring, United States

    1 h-index

    1 publications

    13 citations

  7. University of Cincinnati

    Cincinnati, United States

    1 h-index

    1 publications

    17 citations

  8. Janssen (United States)

    Hopewell, United States

    1 h-index

    2 publications

    22 citations

1–8 of 46

Venues

  1. PubMed

    Repository · 4 publications · 73 citations

    4

    h-index

  2. Journal of Pharmaceutical Sciences

    4 publications · 53 citations

    4

    h-index

  3. Biopharmaceutics & Drug Disposition

    3 publications · 45 citations

    3

    h-index

  4. 1

    h-index

  5. British Journal of Clinical Pharmacology

    BJCP · 1 publications · 125 citations

    1

    h-index

1–5